{"entity":{"type":"insider","cik":"0001660683","url":"/insider/0001660683","json_url":"/insider/0001660683.json","name":"Biotechnology Value Trading Fund OS LP","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":555,"n_filings":141,"first":"2016-01-11","last":"2026-06-26","span_basis":"filed_date"},"name_variants":[{"name":"Biotechnology Value Trading Fund OS LP","source":"filing","n_filings":141,"first_seen":"2016-01-11","last_seen":"2026-06-26"}],"transactions":[{"id":5761149,"accession":"0000921895-26-001688","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000921895-26-001688","line_url":"/filing/0000921895-26-001688","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF Partners OS Ltd.; LAMPERT MARK N; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; BVF INC/IL; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1630658.0,"shares_display":"1,630,658","price_per_share":106.5,"price_display":"106.50","price_state":"stated","total_value":173665077.0,"total_display":"173,665,077.00","total_whole":"173,665,077","shares_owned_after":1960881.0,"shares_owned_after_display":"1,960,881","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-26","filed_date":"2026-06-26","scope":"insider","n_lines":4},{"id":5991670,"accession":"0000921895-26-000895","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-26-000895","line_url":"/filing/0000921895-26-000895","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"MoonLake Immunotherapeutics","issuer_ticker":"MLTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; BIOTECHNOLOGY VALUE FUND II LP; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF PARTNERS L P/IL; LAMPERT MARK N; BIOTECHNOLOGY VALUE FUND L P","owner_display_name":"BVF INC/IL","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Ordinary Shares, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750000.0,"shares_display":"3,750,000","price_per_share":16.79,"price_display":"16.79","price_state":"stated","total_value":62962500.0,"total_display":"62,962,500.00","total_whole":"62,962,500","shares_owned_after":8302735.0,"shares_owned_after_display":"8,302,735","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-31","filed_date":"2026-04-02","scope":"insider","n_lines":3},{"id":5067501,"accession":"0000921895-25-002133","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-25-002133","line_url":"/filing/0000921895-25-002133","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"ESSA Pharma Inc.","issuer_ticker":"EPIX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":156.0,"shares_display":"156","price_per_share":1.8779,"price_display":"1.88","price_state":"stated","total_value":292.9524,"total_display":"292.95","total_whole":"293","shares_owned_after":6194145.0,"shares_owned_after_display":"6,194,145","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-05","filed_date":"2025-08-07","scope":"insider","n_lines":3},{"id":4058547,"accession":"0000921895-25-001910","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-25-001910","line_url":"/filing/0000921895-25-001910","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF GP HOLDINGS LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; LAMPERT MARK N","owner_display_name":"BVF GP HOLDINGS LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":317167.0,"shares_display":"317,167","price_per_share":44.0,"price_display":"44.00","price_state":"stated","total_value":13955348.0,"total_display":"13,955,348.00","total_whole":"13,955,348","shares_owned_after":2798795.0,"shares_owned_after_display":"2,798,795","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-30","filed_date":"2025-07-01","scope":"insider","n_lines":3},{"id":4747320,"accession":"0000921895-25-001602","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-25-001602","line_url":"/filing/0000921895-25-001602","is_derivative":false,"issuer_cik":"0000791908","issuer_name":"XOMA Royalty Corp","issuer_ticker":"XOMA","issuer_name_source":null,"issuer_url":"/issuer/0000791908","owner_cik":null,"owner_name":"BVF INC/IL; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF I GP LLC; LAMPERT MARK N; BVF II GP LLC","owner_display_name":"BVF INC/IL","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0075 par value per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":392723.0,"shares_display":"392,723","price_per_share":27.1,"price_display":"27.10","price_state":"stated","total_value":10642793.3,"total_display":"10,642,793.30","total_whole":"10,642,793","shares_owned_after":1267545.0,"shares_owned_after_display":"1,267,545","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-16","filed_date":"2025-05-20","scope":"insider","n_lines":2},{"id":5067450,"accession":"0000921895-25-000177","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000921895-25-000177","line_url":"/filing/0000921895-25-000177","is_derivative":false,"issuer_cik":"0000791908","issuer_name":"XOMA Royalty Corp","issuer_ticker":"XOMA","issuer_name_source":null,"issuer_url":"/issuer/0000791908","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0075 par value per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":650717.0,"shares_display":"650,717","price_per_share":26.1,"price_display":"26.10","price_state":"stated","total_value":16983713.7,"total_display":"16,983,713.70","total_whole":"16,983,714","shares_owned_after":1450165.0,"shares_owned_after_display":"1,450,165","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-24","filed_date":"2025-01-28","scope":"insider","n_lines":4},{"id":2817990,"accession":"0000921895-24-002409","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-24-002409","line_url":"/filing/0000921895-24-002409","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Third Harmonic Bio, Inc.","issuer_ticker":"THRD","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; BVF INC/IL; LAMPERT MARK N; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF II GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000000.0,"shares_display":"1,000,000","price_per_share":14.3,"price_display":"14.30","price_state":"stated","total_value":14300000.0,"total_display":"14,300,000.00","total_whole":"14,300,000","shares_owned_after":1794218.0,"shares_owned_after_display":"1,794,218","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-29","filed_date":"2024-10-31","scope":"insider","n_lines":3},{"id":2233765,"accession":"0000921895-24-002263","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-24-002263","line_url":"/filing/0000921895-24-002263","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"MoonLake Immunotherapeutics","issuer_ticker":"MLTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF INC/IL; BVF II GP LLC; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; Biotechnology Value Trading Fund OS LP; BVF PARTNERS L P/IL; LAMPERT MARK N; BVF I GP LLC; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND II LP","owner_display_name":"BVF INC/IL","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Ordinary Shares, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000000.0,"shares_display":"2,000,000","price_per_share":50.0016,"price_display":"50.00","price_state":"stated","total_value":100003200.0,"total_display":"100,003,200.00","total_whole":"100,003,200","shares_owned_after":10235089.0,"shares_owned_after_display":"10,235,089","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-04","filed_date":"2024-10-08","scope":"insider","n_lines":3},{"id":2171041,"accession":"0000921895-24-001131","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-24-001131","line_url":"/filing/0000921895-24-001131#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Eledon Pharmaceuticals, Inc.","issuer_ticker":"ELDN","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF INC/IL; LAMPERT MARK N; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF I GP LLC","owner_display_name":"BVF GP HOLDINGS LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1031385.0,"shares_display":"1,031,385","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":3361803.0,"shares_owned_after_display":"3,361,803","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-09","filed_date":"2024-05-13","scope":"insider"},{"id":2171038,"accession":"0000921895-24-001131","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-24-001131","line_url":"/filing/0000921895-24-001131#line-2","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Eledon Pharmaceuticals, Inc.","issuer_ticker":"ELDN","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF INC/IL; LAMPERT MARK N; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF I GP LLC","owner_display_name":"BVF GP HOLDINGS LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":821121.0,"shares_display":"821,121","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":2633679.0,"shares_owned_after_display":"2,633,679","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-09","filed_date":"2024-05-13","scope":"insider"},{"id":2171035,"accession":"0000921895-24-001131","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-24-001131","line_url":"/filing/0000921895-24-001131#line-1","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Eledon Pharmaceuticals, Inc.","issuer_ticker":"ELDN","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF INC/IL; LAMPERT MARK N; BIOTECHNOLOGY VALUE FUND II LP; BVF PARTNERS L P/IL; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF I GP LLC","owner_display_name":"BVF GP HOLDINGS LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":75431.0,"shares_display":"75,431","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":220460.0,"shares_owned_after_display":"220,460","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-09","filed_date":"2024-05-13","scope":"insider"},{"id":8362082,"accession":"0001193805-23-001635","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-23-001635","line_url":"/filing/0001193805-23-001635","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"POINT Biopharma Global Inc.","issuer_ticker":"PNT","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF I GP LLC; LAMPERT MARK N; BVF Partners OS Ltd.; BVF INC/IL; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND L P; BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP","owner_display_name":"BVF I GP LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17161278.0,"shares_display":"17,161,278","price_per_share":12.45,"price_display":"12.45","price_state":"stated","total_value":213657911.1,"total_display":"213,657,911.10","total_whole":"213,657,911","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-18","filed_date":"2023-12-20","scope":"insider","n_lines":3},{"id":8187203,"accession":"0000921895-23-002669","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000921895-23-002669","line_url":"/filing/0000921895-23-002669","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":295745.0,"shares_display":"295,745","price_per_share":5.3837,"price_display":"5.38","price_state":"stated","total_value":1592202.3565,"total_display":"1,592,202.36","total_whole":"1,592,202","shares_owned_after":5309432.0,"shares_owned_after_display":"5,309,432","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-16","filed_date":"2023-11-17","scope":"insider","n_lines":3},{"id":8187189,"accession":"0000921895-23-002669","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-23-002669","line_url":"/filing/0000921895-23-002669","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF Partners OS Ltd.; BVF INC/IL; BVF II GP LLC; BVF I GP LLC; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N","owner_display_name":"BVF PARTNERS L P/IL","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":931556.0,"shares_display":"931,556","price_per_share":4.9999,"price_display":"5.00","price_state":"stated","total_value":4657686.8444,"total_display":"4,657,686.84","total_whole":"4,657,687","shares_owned_after":5155739.0,"shares_owned_after_display":"5,155,739","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-15","filed_date":"2023-11-17","scope":"insider","n_lines":3},{"id":8102416,"accession":"0000921895-23-002475","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000921895-23-002475","line_url":"/filing/0000921895-23-002475","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; LAMPERT MARK N; BVF GP HOLDINGS LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":197699.0,"shares_display":"197,699","price_per_share":14.0689,"price_display":"14.07","price_state":"stated","total_value":2781407.4611,"total_display":"2,781,407.46","total_whole":"2,781,407","shares_owned_after":2656191.0,"shares_owned_after_display":"2,656,191","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-03","filed_date":"2023-11-06","scope":"insider","n_lines":3},{"id":8102407,"accession":"0000921895-23-002475","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-23-002475","line_url":"/filing/0000921895-23-002475","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; LAMPERT MARK N; BVF GP HOLDINGS LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":216406.0,"shares_display":"216,406","price_per_share":11.6444,"price_display":"11.64","price_state":"stated","total_value":2519918.0264,"total_display":"2,519,918.03","total_whole":"2,519,918","shares_owned_after":2020367.0,"shares_owned_after_display":"2,020,367","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-02","filed_date":"2023-11-06","scope":"insider","n_lines":3},{"id":7887682,"accession":"0000921895-23-002458","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-23-002458","line_url":"/filing/0000921895-23-002458","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF GP HOLDINGS LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF INC/IL; BVF PARTNERS L P/IL; BVF I GP LLC; LAMPERT MARK N; BVF II GP LLC; BIOTECHNOLOGY VALUE FUND L P","owner_display_name":"Biotechnology Value Trading Fund OS LP","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":783709.0,"shares_display":"783,709","price_per_share":3.6,"price_display":"3.60","price_state":"stated","total_value":2821352.4,"total_display":"2,821,352.40","total_whole":"2,821,352","shares_owned_after":3792157.0,"shares_owned_after_display":"3,792,157","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-02","filed_date":"2023-11-03","scope":"insider","n_lines":3},{"id":8245370,"accession":"0000921895-23-002167","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-23-002167","line_url":"/filing/0000921895-23-002167","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Olema Pharmaceuticals, Inc.","issuer_ticker":"OLMA","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"BIOTECHNOLOGY VALUE FUND L P; LAMPERT MARK N; BVF I GP LLC; BVF II GP LLC; BVF GP HOLDINGS LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BIOTECHNOLOGY VALUE FUND II LP; BVF INC/IL; BVF PARTNERS L P/IL","owner_display_name":"BIOTECHNOLOGY VALUE FUND L P","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1505932.0,"shares_display":"1,505,932","price_per_share":9.84,"price_display":"9.84","price_state":"stated","total_value":14818370.88,"total_display":"14,818,370.88","total_whole":"14,818,371","shares_owned_after":4688954.0,"shares_owned_after_display":"4,688,954","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-12","filed_date":"2023-09-14","scope":"insider","n_lines":3},{"id":8063646,"accession":"0000921895-23-001098","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-23-001098","line_url":"/filing/0000921895-23-001098#line-3","is_derivative":false,"issuer_cik":"0000918923","issuer_name":"Eledon Pharmaceuticals, Inc.","issuer_ticker":"ELDN","issuer_name_source":null,"issuer_url":"/issuer/0000918923","owner_cik":null,"owner_name":"Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF II GP LLC; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; LAMPERT MARK N; BVF PARTNERS L P/IL; BVF INC/IL","owner_display_name":"Biotechnology Value Trading Fund OS LP","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1055445.0,"shares_display":"1,055,445","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":2330418.0,"shares_owned_after_display":"2,330,418","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-05","filed_date":"2023-05-09","scope":"insider"}],"collapsed":true,"next_cursor":"2023-05-05|8063646","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001815442","name":"Kymera Therapeutics, Inc.","url":"/issuer/0001815442","role":"Director, Other","n_filings":11,"first_seen":"2021-07-06","last_seen":"2026-06-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001821586","name":"MoonLake Immunotherapeutics","url":"/issuer/0001821586","role":"Director, Other","n_filings":2,"first_seen":"2024-10-08","last_seen":"2026-04-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001633932","name":"ESSA Pharma Inc.","url":"/issuer/0001633932","role":"Other","n_filings":1,"first_seen":"2025-08-07","last_seen":"2025-08-07"},{"type":"issuer","type_label":"ISSUER","cik":"0000791908","name":"XOMA Royalty Corp","url":"/issuer/0000791908","role":"Director, Other","n_filings":25,"first_seen":"2018-11-19","last_seen":"2025-05-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001923840","name":"Third Harmonic Bio, Inc.","url":"/issuer/0001923840","role":"Other","n_filings":2,"first_seen":"2022-12-22","last_seen":"2024-10-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001404281","name":"Eledon Pharmaceuticals, Inc.","url":"/issuer/0001404281","role":"Other","n_filings":2,"first_seen":"2023-05-09","last_seen":"2024-05-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001811764","name":"POINT Biopharma Global Inc.","url":"/issuer/0001811764","role":"Other","n_filings":1,"first_seen":"2023-12-20","last_seen":"2023-12-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001808158","name":"Repare Therapeutics Inc.","url":"/issuer/0001808158","role":"Other","n_filings":6,"first_seen":"2022-01-21","last_seen":"2023-11-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001750284","name":"Olema Pharmaceuticals, Inc.","url":"/issuer/0001750284","role":"Director, Other","n_filings":4,"first_seen":"2020-11-20","last_seen":"2023-09-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001724979","name":"Rain Therapeutics Inc.","url":"/issuer/0001724979","role":"Director, Other","n_filings":9,"first_seen":"2021-05-17","last_seen":"2022-11-10"},{"type":"issuer","type_label":"ISSUER","cik":"0000891293","name":"CTI BIOPHARMA CORP","url":"/issuer/0000891293","role":"Director, Ten percent owner, Other","n_filings":4,"first_seen":"2016-01-11","last_seen":"2022-08-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001789972","name":"Cullinan Oncology, Inc.","url":"/issuer/0001789972","role":"Other","n_filings":3,"first_seen":"2022-04-05","last_seen":"2022-06-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001651311","name":"Merus N.V.","url":"/issuer/0001651311","role":"Other","n_filings":14,"first_seen":"2020-01-15","last_seen":"2021-10-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001113148","name":"INFINITY PHARMACEUTICALS, INC.","url":"/issuer/0001113148","role":"Ten percent owner, Other","n_filings":13,"first_seen":"2016-12-02","last_seen":"2021-02-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001676725","name":"IDEAYA Biosciences, Inc.","url":"/issuer/0001676725","role":"Other","n_filings":3,"first_seen":"2020-06-22","last_seen":"2021-02-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001061983","name":"CYTOKINETICS INC","url":"/issuer/0001061983","role":"Other","n_filings":3,"first_seen":"2019-12-12","last_seen":"2020-12-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001175505","name":"FIVE PRIME THERAPEUTICS, INC.","url":"/issuer/0001175505","role":"Other","n_filings":12,"first_seen":"2019-10-08","last_seen":"2020-11-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001253689","name":"GLYCOMIMETICS INC","url":"/issuer/0001253689","role":"Other","n_filings":3,"first_seen":"2019-09-09","last_seen":"2020-11-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001496671","name":"Calithera Biosciences, Inc.","url":"/issuer/0001496671","role":"Other","n_filings":4,"first_seen":"2019-10-31","last_seen":"2020-05-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001583648","name":"PIERIS PHARMACEUTICALS, INC.","url":"/issuer/0001583648","role":"Other","n_filings":1,"first_seen":"2019-09-10","last_seen":"2019-09-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001367920","name":"CONCERT PHARMACEUTICALS, INC.","url":"/issuer/0001367920","role":"Other","n_filings":3,"first_seen":"2017-10-23","last_seen":"2019-06-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001437786","name":"IMMUNE DESIGN CORP.","url":"/issuer/0001437786","role":"Other","n_filings":1,"first_seen":"2018-12-04","last_seen":"2018-12-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001019695","name":"ARQULE INC","url":"/issuer/0001019695","role":"Other","n_filings":3,"first_seen":"2018-04-06","last_seen":"2018-06-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001582313","name":"Xenon Pharmaceuticals Inc.","url":"/issuer/0001582313","role":"Other","n_filings":6,"first_seen":"2017-06-08","last_seen":"2017-08-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001626199","name":"Nivalis Therapeutics, Inc.","url":"/issuer/0001626199","role":"Other","n_filings":5,"first_seen":"2017-05-11","last_seen":"2017-06-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001660683","retrieved_at":"2026-08-22T23:08:13+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}